Each year, IAMI supports millions of dollars of research for a healthier population and creates more than $1 billion dollars for the regional economy.

• IAMI has invested more than $7.9 million in 48 drug, diagnostic, and medical device projects in partnership with research investigators across institutions and organizations. Seven projects receiving IAMI investment have been associated with royalty-bearing license agreements, with two technologies moving into Kansas-based startup companies led by former IAMI fellows and their faculty mentors.
• IAMI's first commercial product, Epaned ^TM, developed in partnership with Silvergate Pharmaceuticals Inc. and Children's Mercy Kansas City, was approved by the FDA and launched in 2013.
• IAMI's collaborations with industry, academia, government and disease philanthropy partners have supported advancement of 10 promising cancer treatments to clinical proof-of-concept trials over the past 6 years.
• IAMI has supported more than $73 million in new federal funding awarded to regional stakeholder institutions and researchers, and currently supports more than $50 million in ongoing research. 
• IAMI actively partners with regional assets in contract drug development (more than 9,000 employees work for over 100 companies and contribute greater than $1 billion to the regional economy each year) to advance drug, diagnostic and medical device projects from the bench to bedside.